In our most listened to episode this year, Certis Oncology CEO Peter Ellman breaks down how his company is reinventing cancer research by building orthotopic patient-derived tumor models that more faithfully mimic human cancer — and using them to improve both drug development and treatment decisions. What is meant by orthotopic? That’s when patient tumors are placed in the “correct place” inside mice to create more faithful cancer models.
Ellman shares the deeply personal origin story behind Certis and explains why their models have changed lives. He discusses the company’s AI-driven predictive platform, now patented, that aims to double drug success rates and usher in truly personalized oncology.
Happy New Year 2026!
